Kymera Therapeutics Reports Third Quarter 2026 Financial Results and Positive KT-579 Phase 1 Data

Kymera Therapeutics reported $1.6 billion in cash as of September 30, 2026, with funding expected to last into 2029; the article did not provide quarterly revenue or profit figures. Phase 1 results for KT-579 showed deep, sustained IRF5 degradation and a favorable safety profile, and Kymera plans to begin a lupus Phase 1b trial by early 2027. The last patient completed the KT-621 BROADEN2 Phase 2b atopic dermatitis trial, with topline results expected by year-end 2026; the company plans a Phase 3 trial by mid-2027 and expects BREADTH Phase 2b asthma data in late 2027. No stock-price movement was reported.